Posts in category: PR Newswire

AUCKLAND, New Zealand, March 2, 2021 /PRNewswire/ — International software development firm Sylo has deployed a highly-usable ‘super-saver’ style ‘Earn’ feature powered by Tezos Baking.

Sylo Smart Wallet users can now earn rewards for the Tez (XTZ) they keep in their wallet, without locking up or losing access to their funds. 

After activating the ‘Earn’ feature in the Sylo Smart Wallet, XTZ holders can then earn rewards while contributing to the network security of a proof-of-stake (PoS) asset. By staking their XTZ, users delegate the voting rights associated with their XTZ to a validator node, also known as a ‘baker’.  

“Bakers are a crucial component in the Tezos Proof-of-Stake (PoS) consensus mechanism,” says David Shin, Head of Asia at TZ APAC. “The deployment of Tezos Baking in the Sylo Smart Wallet will enable users, who delegated their Tez, to be rewarded with additional Tez for securing the network.”

What sets this stake and bake feature apart is the comparative flexibility and ease of access for users, making it ideal for newcomers to crypto.

Whereas other staking and earning programmes may force users to lock up their funds in a contract for a period of time to earn interest, Tezos Baking enables users to have constant access to their funds, allowing them to spend and add more XTZ freely without interfering with the ‘Baking’ process.

“Our design theory for Sylo is always ‘user-first’ and we’ve made Tezos Baking in the Sylo Smart Wallet so straightforward that anyone can use it,” says Ben Jordan, Sylo Co-Founder and Product Director.

“Crypto and DeFi can be simple. Think of earning rewards from Tezos Baking inside the Sylo Smart Wallet like a ‘super-saver’ account for your mobile phone.”

Laid out in the Sylo Smart Wallet with ease of use as a priority, enabling the ‘Earn’ feature is a simple  three-step process.

Built on the foundation of the ‘Buy crypto in-app’ feature recently released to the Sylo Smart Wallet, users can  purchase XTZ inside the app via bank card or transfer and then moments later, activate the ‘Earn’ feature and begin earning rewards by baking their XTZ. Users will receive their first reward after 36 days, then every few days after that.

Tezos Baking in the Sylo Smart Wallet is a growth opportunity for everyday people wanting solid returns or for enthusiasts wanting to put their crypto to work for them. 

The decision to integrate Tezos Baking is just the latest high-profile collaboration to bring value and further use for digital assets to Sylo’s growing user base of over 350,000, which now covers more than 80 countries. More ways for users to get the most out of their digital assets will arrive in the Sylo Smart Wallet as the year progresses.

ABOUT SYLO

Sylo is an international software development house founded in 2010. Committed to decentralisation, they are the core developers of the Sylo Network, the Sylo Protocol and the Sylo Smart Wallet. A next-gen app, the Sylo Smart Wallet sleekly combines a digital asset wallet with a decentralised private messenger. The app allows users to buy crypto in-app, request and receive payments in chat, store and interact with digital assets such as BTC, XTZ, ETH or any ERC-20 compatible token, in a non-custodial wallet, utilise a Web3 Ethereum dApp browser, and pay using cryptocurrency in the real world. For further announcements, follow Sylo on Twitter, Medium or visit www.sylo.io. 

Download the Sylo Smart Wallet from the Google Play or Apple App stores.

ABOUT TZ APAC

TZ APAC Pte. Ltd. (“TZ APAC”) is a leading Asia-based public blockchain consultancy focused on the Tezos ecosystem achieving strategic impact in Asia. TZ APAC designs value-added blockchain transformation strategies for enterprises and startups with a bottom-up approach, working closely with blockchain experts and other stakeholders in the Tezos ecosystem to ensure each strategy is built-in with execution excellence for alignment of business goals with management teams. TZ APAC is supported by the Tezos Foundation and is based in Singapore.

About Tezos

Tezos is smart money, redefining what it means to hold and exchange value in a digitally connected world. A self-upgradable blockchain with a proven track record, Tezos seamlessly adopts tomorrow’s innovations without network disruptions today. To learn more, visit Tezos.com

Download supporting imagery here.

Related Links :

https://www.sylo.io

NEW YORK, March 2, 2021 /PRNewswire/ — Dr. Vanessa Yanhua Zhang has joined The Brattle Group’s New York office as a Principal and the leader of a new Greater China practice. She brings broad experience in applying economic analysis to competition, industrial organization, and intellectual property issues for a global client base across numerous industries. She has extensive relationships in Greater China with leading academics and industry experts.

“Vanessa’s deep understanding of the complex issues our clients are facing in China, the US, and the EU will allow us to expand our existing relationships and build new ones with clients and key opinion leaders in these markets,” said Brattle President & Principal David L. Sunding. “Her joining reflects the truly global reach of our competition practice; we’re thrilled she’s joining Brattle and look forward to many years of success together.” 

Dr. Zhang has analyzed allegations of monopolization, foreclosure practices, vertical restraints, merger analysis, FRAND, and intellectual property in a wide range of matters involving clients in industries including high tech, telecom, consumer products, transportation, and pharma. She has testified as an expert witness and submitted expert reports before the Supreme People’s Court of China, Provincial Higher Courts, the State Administration for Market Regulation (SAMR), the Anti-Monopoly Bureau of Ministry of Commerce (MOFCOM), the National Development and Reform Commission (NDRC), and the Shanghai Administration for Market Regulation (SHAMR).

“For many multinationals, the complexity and geographic scope of global mergers and acquisitions, investigations, and competition and IP disputes continues to expand – as has the need for rigorous expert analyses informed by local and global understanding,” shared Dr. Zhang. “I’m excited to be joining Brattle’s global network, as my clients will greatly benefit from its robust range of capabilities and expert services across North America, Europe, and Asia Pacific.”

Brattle’s China-focused team is composed mainly of experts who are Chinese nationals and bilingual in English and Chinese; 80% of the team hold PhDs in economics from the US or the EU. The team includes highly-regarded academic advisors such as Dr. Jiong John Gong, Professor of Economics at the University of International Business and Economics (UIBE); Dr. Zonglai Kou, Professor of Economics and Deputy Dean of the School of Economics at Fudan University; and Dr. Hongjun Zhong, Professor of Strategy and Economics and the Director of the Faculty Development Center at the Shanghai University of Finance and Economics’s College of Business.

More About Dr. Zhang

Previously, Dr. Zhang was a Managing Director and the head of the Greater China practice at an international economics consulting firm. In addition to her consulting work, she is a Senior Research Fellow at the Renmin University of China Market and Regulation Law Center, and has taught regulation and antitrust economics to graduate students. Dr. Zhang has written numerous articles on China’s merger control regime and Anti-Monopoly Law (AML), and authored extensively for respected publications, including the Journal of Competition Law and Economics, Review of Industrial Organization, and Antitrust Chronicle. She studied economics at Peking University in China and completed her PhD at Toulouse School of Economics in France.

About Brattle

The Brattle Group answers complex economic, finance, and regulatory questions for corporations, law firms, and governments around the world. We are distinguished by the clarity of our insights and the credibility of our experts, which include leading international academics and industry specialists. Brattle has over 400 talented professionals across three continents. For more information, please visit brattle.com.  

Related Links :

http://www.brattle.com

LONDON, March 2, 2021 /PRNewswire/ — On Tuesday, February 23rd 2021, the Prime Minister of the Commonwealth of Dominica, Dr the Hon. Roosevelt Skerrit, took his first jab of the Oxford AstraZeneca vaccine. Several other government ministers, officials and Office staff also joined him. Due to his dynamic leadership and diplomacy, he secured 70,000 vaccinations for Dominica from India. Displaying a kind gesture, the government of Dominica, in partnership with and Barbados, donated some of the vaccines they received to their sister nations and set an example of comradery in the whole Caribbean.

The government also launched a website to get citizens registered and have the vaccination drive be carried out in a phased manner. Currently, Dominica is among the nations which have successfully curbed the pandemic and recorded zero deaths so far. The wise management of the Prime Minister has made the Nature Isle an example for countries worldwide, including CARICOM states, as COVID-19 severely impacts many.

In a webinar that released this week, the Prime Minister emphasised the country’s strong healthcare system. “Because we have had a very robust primary health care system, [it] helped us in containing the presence of COVID-19 in our country,” he said. He also recognised the role of Dominica’s Citizenship by Investment (CBI) Programme as a major sponsor in healthcare advancement. He said, “The Citizenship by Investment Programme has really been a very formidable contributor to our revenue base and also public sector investment programme.”

As the best country for citizenship by investment, according to the Financial Times’ PWM CBI Index, Dominica is well known for making exceptionally good use of CBI contributions. In the healthcare sector alone, the CBI Programme was responsible for constructing many clinics, health centres, and a state-of-the-art hospital scheduled to be completed next month.

Under the Programme, Foreign investors and their families can legally obtain second citizenship from Dominica within three-four months either by making a one-off contribution to a government fund or investing in pre-approved luxury and sustainable hotels. Firstly, though, all applicants must pass Dominica’s thorough due diligence checks, deemed among the most rigorous of all investor immigration programmes. This guarantees the Programme’s integrity for Dominica’s sake, while investors can rest assured that their citizenship is for life and can safely be passed on to future generations.

Economic citizens earn the right to live, work and study in Dominica, taking advantage of all the country’s facilities, such as good healthcare, education, visa-free travel, safety and security for life.

Contact: pr@csglobalpartners.com, www.csglobalpartners.com  

YIWU, China, March 2, 2021 /PRNewswire/ — Yiwugo.com, the official website of the Yiwu Commodity Market, which is the largest commodity wholesale market in the world, recently announced the official start of its call for global partners for 2021, inviting import and export trade service enterprises across the world to become its partners and jointly explore the global commodity wholesale market.

Relying on the advantageous commodity supply chain of the Yiwu market, Yiwugo is committed to building a world-leading online commodity trading platform. To date, Yiwugo has played host to more than 53,000 quality commodity suppliers, providing more than 5 million kinds of commodities, attracted a daily average of more than 800,000 visitors, and accommodated more than 6 million registered buyers. The program of Yiwugo’s call for global partners has been launched in Canada, Egypt, Indonesia and other regions. According to the feedback from its partners, Yiwugo has improved and upgraded support for its partners in 2021, with a focus on assisting them in increasing their effective trade volume:

I. Providing technical support for the construction of online substation sites

Yiwugo’s global partners will engage in business cooperation mainly through Yiwugo’s online substation sites. For partners who encounter technical difficulties in building online substation sites, Yiwugo will provide technical support to help them build local online substation sites.

II. Help partners establish commodity libraries according to the regional market characteristics

According to the characteristics of the partners’ local markets, Yiwugo will assist them in selecting products that suit the local demands from the Yiwugo platform and display them on their Yiwugo online substation sites for local buyers to purchase.

III. Bring inquiries to partners relying on the Yiwugo brand

When buyers in a partner’s region visit the Yiwugo website, they will be automatically diverted to the partner’s local substation so that the partner may provide localized procurement services for them; procurement inquiries from the region will also be transferred to the partner for follow-up.

IV. Provide after-sales services

After the buyer places an order, the partner can forward the buyer’s purchase demand to Yiwugo’s headquarters, which will conduct goods assembly and inspection and send the goods to the partner’s local warehouse, thus saving the partner from the trouble of selecting goods in Yiwu and ensuring better quality of the goods.

Yiwugo looks forward to cooperating with foreign trade service enterprises that intend to move their offline business online. Partners with physical business premises and capable of dealing with foreign exchange trading with RMB are preferred.

If you are interested in becoming Yiwugo’s partner, please contact us by the following methods:

Contact us:
E-mail: overseas@yiwugo.com
Facebook: www.facebook.com/yiwugo
Twitter: www.twitter.com/yiwugou
https://zt.yiwugo.com/dataservice/index.html#jobhot&spm=d3d3Lnlpd3Vnby5jb20v

Related Links :

https://en.yiwugo.com/

77,000 Sci-Tech Assistance Pairs have been set up and 289,800 sci-tech commissioners have been selected successfully to help the poor out of poverty.

BEIJING, March 1, 2021 /PRNewswire/ — A report from Science and Technology Daily:

The fungus from Zhashui went popular.

On April 20, 2020, President Xi Jinping went to Zhashui, Shaanxi to inspect the work of poverty alleviation and praised that the small fungus has formed a large industry.

“The president’s praise affirms the tangible role of sci-tech poverty alleviation industries, including fungi, in poverty alleviation.” Li Yu, academician of the Chinese Academy of Engineering and professor of Jilin Agricultural University, said excitedly.

“90% mountains, 5% water and 5% fields” is a true portrayal of Zhashui, a targeted county for poverty alleviation by the Ministry of Science and Technology (MOST). With the aid of technology, small fungus has gradually formed a large industry. Delicious, big, thick… The black fungus and jade fungus selected by Li Yu’s team played a hard-core role in the poverty alleviation of Zhashui and the prosperity of its people.

Poverty alleviation through science and technology is an important part of the national poverty alleviation and development strategy. The sci-tech poverty alleviation action is one of the top ten poverty alleviation actions determined by the State Council’s Leading Group of Poverty Alleviation and Development in 2016.

Since the 18th National Congress of the Communist Party of China (NCCPC), the MOST has firmly grasped the poverty alleviation strategy: targeted poverty alleviation, the will to fight against poverty should be put ahead of poverty alleviation, and the knowledge and skills needed should be provided at the same time. It deeply implemented the sci-tech poverty alleviation project of “A hundred platforms, A thousand assistance pairs, Ten thousand commissioners”, innovated mechanisms of inter-ministerial coordination, eastern and western sci-tech poverty alleviation cooperation and “four-level linkage”, establishing a large pattern of sci-tech poverty alleviation: “Horizontally to the Side, Vertically to the End”.

The poverty alleviation work through science and technology has made significant achievements. The sci-tech departments of all levels in China have established 1,290 innovation and entrepreneurship platforms in poverty-stricken areas, established 77,000 sci-tech assistance pairs, selected 289,800 sci-tech commissioners, invested more than 20 billion RMB, implemented 37,600 projects, and promoted the application of more than 50,000 advanced and practical technology new varieties.

Regard the development of industries with rural characteristics as the main front

Li Yu is the only academician in the field of edible and medicinal fungi research in China. Changchun and Zhashui are 2102 kilometers apart. Why has the fungus of Li Yu’s team got a good harvest in Zhashui?

There is a moving story about poverty alleviation through science and technology. In 2017, led by the MOST, Li Yu’s team went to Zhashui and started their sci-tech poverty alleviation work.

“Science and technology achieved significant results in poverty alleviation in Zhashui and other places. The key lies in the development of industries with rural characteristics as the main front.” The person in charge from the MOST said.

In Zhashui, the MOST has implemented 28 special projects for the central-guided local science and technology development, invested 70.5 million RMB, introduced more than 380 scientific and technological talents, and organized training for more than 3,000 person-time poverty alleviation officials and poverty-stricken people.

In July 2016, during an inspection in Ningxia, President Xi Jinping pointed out that developing industries is the fundamental way to achieve poverty alleviation. It is necessary to adapt measures to local conditions and to cultivate industries as the fundamental way out of poverty alleviation.

Since the 18th NCCPC, sci-tech departments of all levels in China have implemented 37,600 sci-tech projects at all levels in poverty-stricken areas, including national key R&D programs and special projects for the central-guided local science and technology development, leading the rapid development of poverty alleviation industries.

More than 66 million RMB has been invested in the national key R&D programs “high-quality and high-yield major cash crops and the improvement of quality and efficiency of sci-tech innovation by industries”, “blue granary sci-tech innovation”, “key technology R&D for food safety” and other key special projects to make aquaculture, fungus and rare edible mushrooms industries larger and stronger.

The popularization and application of technologies for the breeding of Coptis chinensis new varieties, high-efficiency cultivation, comprehensive utilization of by-products and other technologies has enabled the comprehensive output value of the Coptis chinensis industry in Shizhu, Chongqing to reach 360 million RMB, and the average income of growers is 46,000 RMB.

Luopu County, Xinjiang has integrated poverty alleviation funds of more than 60 million RMB to build the largest pigeon breeding base in Hotan area, receiving 193 poor people to work and driving 7,900 poor households out of poverty with income increase of more than 1,000 RMB per capita.

The sci-tech departments of all levels in China have promoted the application of more than 50,000 advanced practical technologies and new varieties such as “integrated rice-fishing cultivation technology” and “smash-ridging technology”, which injected strong momentum into the high-quality development of industries in poor areas.

The sci-tech commissioners become a new force in the fight against poverty

In 2015, Zhu Youyong, a 60-year-old sci-tech commissioner and an academician of the Chinese Academy of Engineering, came to his hometown of Lancang County, Yunnan’s most impoverished area. He set himself a new goal: to use science and technology to eradicate poverty.

He has been stationed in the Haozhiba village, Lancang for poverty alleviation, who is a sci-tech commissioner to set up an academician work station in the grass-rooted unit in China.

Zhu Youyong, who is nicknamed as the “farmer academician” by the local people, promoted the transformation of scientific and technological achievements based on the actual situation in rural areas, and established the academician science and technology poverty alleviation training class.

At present, under-forest organic Panax notoginseng planting has been promoted in the poverty-stricken mountainous areas of Lancang for more than 1,000 mu (around 1700 acres), and late-season potatoes have been promoted in Yunnan province for over 5 million mu (around 0.83 million acres).

“Poverty alleviation through science and technology has enabled us to transform ‘idle winter fields’ into ‘productive fields’ and develop a winter potato industry in Lancang.” Zhu Youyong said.

On October 20, 2019, President Xi Jinping issued important instructions on the 20th anniversary of the implementation of the sci-tech commissioner system.

Xi said that since the implementation of the system, more and more experts have been sent to the countryside to serve agriculture, rural areas and farmers with science and technology in the past 20 years. They have helped publicize the Party’s policies on agriculture, rural areas and farmers, popularize agricultural science and technology, spearhead sci-tech innovation and entrepreneurship in rural areas, and lead villages out of poverty. “They have enabled farmers to acquire a stronger sense of fulfillment and and happiness,” he also said.

Since the 18th NCCPC, experts selected by the sci-tech departments of all levels in China have been dispatched to the frontline of poverty alleviation, basically achieving full coverage of science and technology services and promotion of entrepreneurship in nearly 100,000 registered poverty-stricken villages across the country. They set great example to farmers and led them out of poverty. During the process, some advanced examples emerged, such as Li Yu, Zhao Yafu, Yao Jianmin, Lyu Xiulan, and Zhu Youyong.

Since 2014, the central government has invested a total of 2.14 billion RMB to implement the “Three Districts” Talent Support Program for special scientific and technological talents. More than 120,000 scientific and technological talents have been selected to 1,118 “Three Districts” counties in central and western provinces. Besides, more than 20,000 local talents who are skilled in technology, operation and management were trained, and most of them are returning migrant workers and college graduates working as village officials. All these measures were taken to create a working team labeled as being perseverant and professional for poverty-stricken areas .

We will develop demonstration field for innovation-driven targeted poverty alleviation

In January 2016, President Xi Jinping inspected the poverty alleviation work in Jinggangshan and pointed out that “Jinggangshan should set an example and lead the way in poverty alleviation”.

The MOST always adheres to the path of innovation-driven development and builds targeted poverty alleviation counties into innovation-driven precision poverty alleviation demonstration fields. It has selected and sent a group of officials with strong business skills and sci-tech experts, and implemented scientific and technological projects with great effects. Besides, a number of innovative and entrepreneurial platforms have been established, and a group of distinctive and sustainable poverty alleviation industries have been developed.

Statistics show that the MOST has invested more than 1.1 billion RMB and introduced assistance funds in 5 targeted poverty alleviation counties since 2016. The MOST also implemented more than 250 projects including the national key research and development plan, the special project of the central-guided local science and technology development, and the special project of “Science & Technology Boosts the Economy 2020” with a total of 219 million RMB has been invested. About 845 million RMB has been introduced for assistance, nearly 200 new varieties have been selected, and more than 100 key industrial technologies have been developed, which has effectively improved the technological level of industrial development in targeted poverty alleviation counties.

In the five targeted poverty alleviation counties, the MOST has set up more than 30 platforms for innovation and entrepreneurship, including national and provincial agricultural science and technology parks, service space for innovators, sub-centers for collaborative innovation, science and technology demonstration bases, industrial demonstration parks, and science and technology resource coordination centers, to facilitate the deep integration of scientific and technological innovation with industries, and to improve the quality and efficiency of poverty-alleviation leading industries.

As of 2018, the MOST had selected 65 poverty alleviation officials from the 30 sessions of the Science and Technology Poverty Alleviation Group to Jinggangshan, a targeted poverty alleviation county, supported a total of 338 projects in 35 key poverty-stricken villages, with a total investment of 345 million RMB.

All of the MOST’s five targeted poverty alleviation counties have shaken off poverty ahead of schedule. Among them，Jinggangshan took the lead and made president Xi’s words about “Jinggangshan should set a good example in the fight against poverty” come true.

Targeted measures should be taken to ensure that assistance reaches poverty-stricken villages and households.

The premise of rural revitalization is industrial prosperity.

The less developed the regions are, the more innovation-driven development strategies they need to implement.

The whole Party and the whole society should continue to work together to form a strong synergy in poverty alleviation and development.

The statements above are resounding.

Achieving poverty alleviation through science and technology lies in its work precision，focusing on industry, taking root in innovation, depending on people’s joint effort and relies on persistence.

Since the 18th NCCPC, the sci-tech departments of all levels in China have explored a path of innovation-driven targeted poverty alleviation by leveraging the advantages of science and technology and human resources.

Eradication of poverty is not the end, but a fresh start of the new life and the new strive. In this land of hope, science and technology will create more opportunity, consolidate and expand China’s anti-poverty achievements, promote rural revitalization in all respects, and make new and greater contributions to achieving new victories in building China into a great modern socialist country in all respects.

SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the first patient outside China has been successfully dosed in a Phase 1 clinical trial of the potentially first-in-class recombinant anti-CD47/PD-L1 bispecific antibody (IBI322).

This is a Phase 1a clinical study conducted in the United States to evaluate IBI322 in the treatment of patients with advanced malignancies. The primary objective of the study is to evaluate the safety, tolerability, and initial anti-tumor efficacy of IBI322 in patients with advanced malignancies who have failed standard therapy.

IBI322 is a recombinant anti-CD47/PD-L1 bispecific antibody that blocks both the PD-1/PD-L1 and CD47/ SIRP-α pathways. Pre-clinical studies showed that IBI322 can effectively block CD47–SIRP-α interactions and induce macrophages to phagocytize CD47 expressed tumor cells, which is equivalent to anti-CD47 monoclonal antibody. IBI322, on the other way, effectively blocks the binding of PD-1 to PD-L1 and activates CD4+T lymphocyte, which is comparable to anti-PD-L1 monoclonal antibody. Because of PD-L1 expression on tumor cells, IBI322 can selectively binds to tumor cells more potent than anti-CD47 monoclonal antibody, thus reducing the possibility of bind to CD47 on red blood cells, which could ultimately reduce the toxicity associated with anti-CD47 antibodies. Therefore, IBI322 has better antitumor activity and higher safety profile.

Although immune checkpoint inhibitors have shown promising results in the treatment of a wide range of tumors, there still remains many new challenges. A part of patients has developed drugs resistance and the efficacy of immune checkpoint inhibitors needs to be further enhanced. Therefore, it is of great value to develop the next generation of anti-tumor immune bispecific antibodies. CD47 is one of the most promising targets among cancer immunotherapy, combining innovative techniques for bispecific monoclonal antibody, we look forward to the results of IBI322 clinical trials.

Dr. Hui Zhou, Vice President and Head of Oncology Strategy and Medical Sciences of Innovent, stated: ” By targeting effector cells directly to tumor cells, bispecific monoclonal antibody enhances cytotoxicity, antibody selectivity and functional affinity. The preliminary results showed that IBI322 had higher efficacy in vivo, tumor-rich distribution and better safety than the single-specific anti-CD47 antibody. Bispecific monoclonal antibody could bring a lower-cost solution to patients compared with a combination of monoclonal antibody therapies. Therefore, the development of the anti-CD47/PD-L1 bispecific antibody will provide patients with a novel, comprehensive, effective and cost-saving treatment regimen. We hope IBI322 could potentially benefit more patients in need.”          

About IBI322

IBI322 is a recombinant anti-CD47/PD-L1 bispecific antibody developed by Innovent. As a class 1 innovative drug and a potentially first-in-class molecule, IBI322 can effectively induce the phagocytosis of tumor cells and stimulate the activation of T lymphocytes to exert anti-tumor activity. IBI322 is of more affinity to tumor cells, thus reducing the toxicity to normal tissue, providing more effective treatment to cancer patients. IBI322 has received an IND approval from both the NMPA and the U.S. FDA. Innovent is actively preparing to develop it globally.

About Innovent

Inspired by the spirit of “Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with 4 products – TYVYT^® (sintilimab injection), BYVASDA^® (bevacizumab biosimilar injection), SULINNO^® (adalimumab biosimilar injection) and HALPRYZA^® (rituximab biosimilar injection) – officially approved for marketing in China, four assets in Phase 3 or pivotal clinical trials, and additional 15 molecules in clinical trials. TYVYT^® was included in the National Reimbursement Drug List (NRDL) in 2019 as the historically first PD-1 inhibitor entering in NRDL and the only PD-1 included in the list in that year.

Innovent has built an international team of advanced talents in high-end biological drug development and commercialization, including many overseas experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. Innovent strives to work with all relevant parties to help advance China’s biopharmaceutical industry, improve drug availability to ordinary people and enhance the quality of the patients’ lives.  For more information, please visit: www.innoventbio.com.

Related Links :

http://www.innoventbio.com

SHANGHAI and HONG KONG, Feb. 28, 2021 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the company has been selected as a constituent stock of the Hang Seng Composite Index (HSCI), the Hang Seng Stock Connect Hong Kong Index (HSHKI), the Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index (HSHKMS), the Hang Seng Stock Connect Hong Kong SmallCap Index (HSHKS), the Hang Seng SCHK Mainland China Companies Index (HSSCMLC), the Hang Seng SCHK ex-AH Companies Index (HSSCNAH), the Hang Seng Healthcare Index (HSHCI), the Hang Seng Hong Kong-Listed Biotech Index (HSHKBIO) and the Hang Seng Small Cap (Investable) Index (HSSIV), according to the quarterly review results of the Hang Seng Family of Indexes, effective on March 15, 2021.

The Hang Seng Composite Index offers a comprehensive Hong Kong market benchmark that covers about the top 95th percentile of the total market capitalization of companies listed on the Main Board of the Stock Exchange of Hong Kong (SEHK). Adopting the free float-adjusted market capitalization methodology, the HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks. The Hang Seng Stock Connect Hong Kong Index serves as a benchmark to reflect the overall performance of the securities listed in Hong Kong that are eligible for trading via the southbound trading link of Stock Connect; the Hang Seng Healthcare Index aims to reflect the overall performance of stocks listed in Hong Kong that are related to healthcare businesses; and the Hang Seng Hong Kong-Listed Biotech Index reflects the overall performance of the biotech companies that are listed in Hong Kong including stocks listed through the Listing Rules Chapter 18A of Hong Kong Exchange.

Antengene has the world’s only commercialized selective inhibitor of nuclear export (SINE), ATG-010 (selinexor), and with its successful IPO in November 2020, is one of the fastest growing Hong Kong-listed biopharmaceutical companies. In the past half a year, Antengene has achieved multiple milestones in clinical and business developments, and has submitted New Drug Applications (NDAs) in five APAC markets including China. Moreover, ATG-010 was granted Priority Review status by the China National Medical Products Administration (NMPA) and an Orphan Drug Designation by the Ministry of Food and Drug Safety of South Korea (MFDS). These progress have taken the company one step closer to providing a novel therapeutic option to cancer patients.

“It is our great pleasure to see Antengene being included into nine indexes in the Hang Seng Family of Indexes. These inclusions will give Antengene greater exposure in the capital markets and further improve our visibility among the broader investor community,” said Dr. Jay Mei, Founder, Chairman and CEO of Antengene. “Our innovative products that are on the brink of commercialization, our fast-growing commercial team, and our clinical team possessing strong track record in the field of hematological malignancy are the source of our confidence in Antengene’s future growth. We will remain committed to our founding mission of ‘treating patients beyond borders’, and steadfastly pursue long-term growth in the field of innovative anti-tumor therapies.”

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the Asia Pacific Region and around the world. Since its establishment, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets and obtained 12 investigational new drug approvals in Asia Pacific. The vision of Antengene is to “Treat Patients Beyond Borders”. Antengene aims to address significant unmet medical needs by discovering, developing and commercializing first-in-class/best-in-class therapeutics.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

SHISHI, China, Feb. 26, 2020 /PRNewswire/ — KBS Fashion Group Limited (“KBS” or the “Company”) (NASDAQ: KBSF), a leading fully-integrated casual menswear company in China, announced today that its Board of Directors approved a Binding Memorandum of Understanding (the “MOU”) regarding an exempt private offering of convertible preferred stock in the amount of up to $1,500,000 to a single investor. Under the MOU, the investor will purchase up to 100,000 shares of convertible preferred stock at a price of $15 per share. Each share of preferred stock will be convertible to shares of our common stock at a ratio of 15 shares of common stock for each share of preferred stock. All shares of common stock issuable upon conversion of the preferred stock will be subject to a two-year lock-up agreement running from the initial closing of the financing. Conversions will be limited such that the investor may not effect a conversion of the preferred stock to the extent that, immediately after such conversion, the investor would be the beneficial owner of more than 9.99% of our issued and outstanding common stock.

Formal documentation of the proposed private offering is pending and the offering is expected to close in the near future. 

The proceeds are intended to be used by Flower Crown Holding (“FCH”), a fully owned subsidiary of KBSF, for its continuing business expansion. FCH is the owner of Luxventure, a social media platform launched in July of 2020 offering cross border merchandise through online and off-line channels and luxury tourism experiences to its members.  Luxventure has entered into cooperation agreements with over 15 major corporations such as CITIC International Travel (Guangdong) Co., Ltd, Hangzhou Youzan Technology Co., Ltd. and Beijing Space Transformation Technology Co., Ltd, a subsidiary of Bytedance.

As one of the very few companies in China with the licenses to source, distribute and sale of cross border luxury merchandise, Luxventure offers its members a significant discount to its competitors’ price. In January of 2021, Luxventure formed a strategic partnership with a subsidiary of Hainan Strait Shipping Co., Ltd (“HSS”), which operates 45 cruise vessels in Hainan Island, for self-owned stores. For the year 2021, those cruise vessels are expected to have over 20,000,000 visitors. In January of 2021, Luxventure recruited Mr. Liu Ze, an expert in Artificial Intelligence and Blockchain, for its e-commerce portal. 

Ms. Sun Lei, Chief Executive Officer of the Company commented: “We are proud of what Luxventure had accomplished in a short time. International travel restriction has increased demand for domestic travel and crossed border mechandise. Chinese consumers have flocked to Hainan Island to take advantage of its COVID-19 free environment and duty-free shopping. Sales of crossed border merchandise in China is one of the very few areas which had minimal impact by COVID-19. Given China’s designation of Hainan Island as a free port and Luxventure’s strong competitive advantage, this investment would allow it to further expand into this business.” 

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About KBS Fashion Group Limited

Headquartered in Shishi, China, KBS Fashion Group Limited, through its subsidiaries, is engaged in the business of designing, manufacturing, selling and distributing its own casual menswear brand, KBS, through a network of 30 KBS branded stores (as of Dec 31, 2019) and over a number of multi-brand stores. To learn more about the Company, please visit its corporate website at www.kbsfashion.com.

Safe Harbor Statement

This press release may contain certain “forward-looking statements” relating to the business of KBS Fashion Group Limited, and its subsidiary companies. All statements, other than statements of historical fact included herein, are “forward-looking statements” in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Related Links
http://www.kbsfashion.com

SEOUL, South Korea, Feb. 26, 2021 /PRNewswire/ — Shinhan Perkasa Holdings, a market-leading boutique wealth management company located in Seoul, has today announced a recent promotion. 

Ko Yeon-Hong, a long-term employee of the company who has most recently held the role of Human Resources Assistant, has been promoted to Human Resources Director. 

The Human Resources Director will be responsible for the smooth and profitable operation of our human resources department. Yeon-Hong will supervise and provide consultation to management on strategic staffing plans, compensation, benefits, training and development, budget, and labour relations.

“This promotion reflects our company’s commitment to excellence,” said Chief Executive Officer at Shinhan Perkasa Holdings, Hak Dong-Gun. “We have built a high performing team that requires we recognise and retain individuals for their leadership and contributions. Ko has exemplified our company’s highest standards of integrity. She is a passionate team player who has consistently developed new strategies that exceed our expectations while assisting with the growth of our business.”

Yeon-Hong joined Shinhan Perkasa Holdings in 2016 and has proven herself by focusing on delivering effective human resource solutions throughout her career history with the company. She will now be responsible for overseeing the entire Human Resources team whilst keeping the company’s core principles at the centre of all corporate recruitment and business growth issues.  

“I have worked with Ko since she started and nobody is better for this role. During our time together, we have developed a close working relationship and have shared many of the same ideas in terms of growth strategies for my team and our company,” said Ralph Johnson, Director of Global Corporate Markets at Shinhan Perkasa Holdings.

Shinhan Perkasa Holdings provides all its team members the opportunity to enhance their abilities by being dedicated to fostering a bright, team-focused working environment which keeps one ear open for feedback and suggestions from the inside and considers the preferences of all its members.

About Shinhan Perkasa Holdings

Headquartered in the heart of Seoul, South Korea, Shinhan Perkasa Holdings is a respected pioneer in wealth management and investment advisory.

Related Links :

https://sphinternational.com

BEIJING, Feb. 26, 2021 /PRNewswire/ — Puxin Limited (NYSE: NEW) (“Puxin” or the “Company”), a successful consolidator of the after-school education industry in China, today announced that it has entered into convertible note purchase agreements with a group of institutional investors (the “Purchasers”), pursuant to which Puxin will issue and sell convertible notes in an aggregate principal amount of US$69 million through a private placement to the Purchasers. The transaction is subject to the satisfaction of customary closing conditions.

The convertible notes will mature in five years, bearing interest at the rate of 3% per annum from the issuance date which shall be payable semiannually in arrears in cash. Subjected to and upon compliance with the terms of the convertible notes, each Purchaser has the right to convert all or any portion of the convertible notes at its option at any time after the issuance into ordinary shares of the Company represented by American depositary shares (“ADSs”). Unless previously redeemed or converted, the Company shall repay the notes on the maturity date at 100% of the then outstanding principal amount plus all accrued but unpaid interest. 

Safe Harbor Statement

This press release contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “may,” “would,” “expect,” “anticipate,” “future,” “intend,” “aim,” “plan,” “believe,” “estimate,” “predict,” “project,” “continue,” “confident” and similar statements. The Company may also make written or oral forward-looking statements in its reports filed with or furnished to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but not limited to the following: its goals and strategies, its ability to achieve and maintain profitability, its ability to attract and retain students to enroll in its courses, its ability to effectively manage its business expansion and successfully integrate businesses it acquired, its ability to identify or pursue targets for acquisitions, its ability to compete effectively against its competitors, its ability to improve the content of its existing courses or to develop new courses, and relevant government policies and regulations relating to the Company’s corporate structure, business and industry. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is current as of the date of the press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

About Puxin Limited

Puxin Limited (NYSE: NEW, “Puxin” or the “Company”) is a successful consolidator of the after-school education industry in China. Puxin has a strong acquisition and integration expertise to effectively improve education quality and operational performance of acquired schools. Puxin offers a full spectrum of K-12 and study-abroad tutoring programs designed to help students achieve academic excellence, as well as prepare for admission tests and applications for top schools, universities and graduate programs in China and other countries. The Company has developed a business model effectively combining strategic acquisitions and organic growth achieved through successful post-acquisition integration, which has differentiated the Company from other after-school education service providers in China. For more information, please visit http://www.pxjy.com/.

Contacts

Puxin Limited

Phone: +86-10-6269-8930
E-mail: ir@pxjy.com

ICA (Institutional Capital Advisory)

Mr. Kevin Yang
Phone: +86-021-8028-6033
E-mail: puxin@icaasia.com

Related Links :

http://www.pxjy.com